๎
๎ผ
๎
Elicio Therapeutics Inc
ELTX8.195USD
+0.255+3.21%
์์ฅ ์ด์ ์๊ฐย ๏ผET๏ผ์์ธ๋ 15๋ถ ์ง์ฐ๋ฉ๋๋ค
141.43M์๊ฐ์ด์ก
์์คP/E TTM
๎
์์ธํ ๋ด์ฉ์ Elicio Therapeutics Inc ํ์ฌ
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Companyโs clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.
Elicio Therapeutics Inc ์ ๋ณด
๎์ข
๋ชฉ ์ฝ๋ ELTX
ํ์ฌ ์ด๋ฆElicio Therapeutics Inc
์์ฅ์ผFeb 05, 2021
CEOConnelly (Robert)
์ง์ ์32
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃFeb 05
์ฃผ์451 D Street, 5Th Floor
๋์BOSTON
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐUnited States of America
์ฐํธ ๋ฒํธ02459
์ ํ18572090050
์น์ฌ์ดํธhttps://elicio.com/
์ข
๋ชฉ ์ฝ๋ ELTX
์์ฅ์ผFeb 05, 2021
CEOConnelly (Robert)
Elicio Therapeutics Inc์ ํ์ฌ ์์์ง
๎์ด๋ฆ
์ด๋ฆ/์ง์
์ง์
์ฃผ์ ๋ณด์
๋ณ๋
Dr. Jay R. Venkatesan, M.D.
Dr. Jay R. Venkatesan, M.D.
Director
Director
170.22K
-5.71%
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Independent Director
Independent Director
12.72K
--
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
1.87K
--
Dr. Peter Demuth, Ph.D.
Dr. Peter Demuth, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
743.00
+95.01%
Dr. Julian Adams, Ph.D.
Dr. Julian Adams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Executive Vice President, Head - Research and Development, Chief Medical Officer
Executive Vice President, Head - Research and Development, Chief Medical Officer
--
--
Ms. Carol Ashe
Ms. Carol Ashe
Independent Director
Independent Director
--
--
Dr. Allen R. Nissenson, M.D.
Dr. Allen R. Nissenson, M.D.
Independent Director
Independent Director
--
--
Dr. Robert R. Ruffolo, Jr.
Dr. Robert R. Ruffolo, Jr.
Independent Director
Independent Director
--
--
Mr. Robert (Bob) Connelly
Mr. Robert (Bob) Connelly
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
๋ ๋ณด๊ธฐ
์ด๋ฆ
์ด๋ฆ/์ง์
์ง์
์ฃผ์ ๋ณด์
๋ณ๋
Dr. Jay R. Venkatesan, M.D.
Dr. Jay R. Venkatesan, M.D.
Director
Director
170.22K
-5.71%
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Independent Director
Independent Director
12.72K
--
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
1.87K
--
Dr. Peter Demuth, Ph.D.
Dr. Peter Demuth, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
743.00
+95.01%
Dr. Julian Adams, Ph.D.
Dr. Julian Adams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Executive Vice President, Head - Research and Development, Chief Medical Officer
Executive Vice President, Head - Research and Development, Chief Medical Officer
--
--
์์ต ๋ถ์
๊ธฐ์
์ด ์์ง ๊ด๋ จ ๋ฐ์ดํฐ๋ฅผ ๊ณต๊ฐํ์ง ์์์ต๋๋ค.
๊ธฐ์
์ด ์์ง ๊ด๋ จ ๋ฐ์ดํฐ๋ฅผ ๊ณต๊ฐํ์ง ์์์ต๋๋ค.
์ฌ์
๋ณ
์ง์ญ๋ณ
๊ธฐ์
์ด ์์ง ๊ด๋ จ ๋ฐ์ดํฐ๋ฅผ ๊ณต๊ฐํ์ง ์์์ต๋๋ค.
์ฃผ์ ๋ณด์ ํต๊ณ
๋ง์ง๋ง ์
๋ฐ์ดํธ: Sun, Nov 23
๋ง์ง๋ง ์
๋ฐ์ดํธ: Sun, Nov 23
์ฃผ์ฃผ
์ฃผ์ฃผ ์ ํ
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น์จ
GKCC, LLC
30.97%
Knoll Capital Management, LLC
3.61%
Clal Biotechnology Industries Ltd
2.75%
The Vanguard Group, Inc.
2.71%
Actyus Private Equity SGIIC, S.A.
1.54%
๊ธฐํ
58.42%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น์จ
GKCC, LLC
30.97%
Knoll Capital Management, LLC
3.61%
Clal Biotechnology Industries Ltd
2.75%
The Vanguard Group, Inc.
2.71%
Actyus Private Equity SGIIC, S.A.
1.54%
๊ธฐํ
58.42%
์ฃผ์ฃผ ์ ํ
์ฃผ์ฃผ
๋น์จ
Corporation
32.50%
Hedge Fund
4.86%
Investment Advisor
4.52%
Holding Company
2.75%
Investment Advisor/Hedge Fund
2.25%
Individual Investor
1.51%
Research Firm
0.18%
๊ธฐํ
51.42%
๊ธฐ๊ด ์ฃผ์ ๋ณด์
๎๋ง์ง๋ง ์
๋ฐ์ดํธ: Mon, Dec 8
๋ง์ง๋ง ์
๋ฐ์ดํธ: Mon, Dec 8
๋ณด๊ณ ๊ธฐ๊ฐ
๊ธฐ๊ด ์
๋ณด์ ์ฃผ์
๋น์จ
๋ณ๋
2025Q4
58
2.05M
11.00%
--
2025Q3
59
2.05M
11.96%
+477.65K
2025Q2
52
1.58M
11.53%
-116.12K
2025Q1
59
1.67M
8.91%
+250.74K
2024Q4
54
504.27K
8.35%
-37.38K
2024Q3
58
541.64K
9.80%
-115.54K
2024Q2
70
657.30K
8.80%
+242.22K
2024Q1
96
415.08K
8.40%
-443.93K
2023Q4
102
540.87K
10.06%
+911.00
2023Q3
115
547.56K
11.25%
+45.29K
๋ ๋ณด๊ธฐ
์ฃผ์ฃผ ํ๋
๎์ด๋ฆ
๋ณด์ ์ฃผ์
๋น์จ
๋ณ๋
Chg %
๋ ์ง
GKCC, LLC
5.42M
33.15%
--
--
Jun 03, 2025
Knoll Capital Management, LLC
630.91K
3.86%
--
--
Jun 30, 2025
Clal Biotechnology Industries Ltd
481.73K
2.95%
-52.31K
-9.80%
Apr 09, 2024
The Vanguard Group, Inc.
454.62K
2.78%
+132.93K
+41.32%
Jun 30, 2025
Actyus Private Equity SGIIC, S.A.
856.38K
5.24%
+268.56K
+45.69%
Mar 31, 2025
Venkatesan (Jay R)
170.22K
1.04%
-10.31K
-5.71%
Mar 24, 2025
Geode Capital Management, L.L.C.
120.83K
0.74%
+43.36K
+55.98%
Jun 30, 2025
Susquehanna International Group, LLP
17.02K
0.1%
-14.34K
-45.72%
Jun 30, 2025
๋ ๋ณด๊ธฐ
๊ด๋ จ ETF
๎๋ง์ง๋ง ์
๋ฐ์ดํธ: Sat, Dec 6
๋ง์ง๋ง ์
๋ฐ์ดํธ: Sat, Dec 6
์ด๋ฆ
๋น์จ
iShares Micro-Cap ETF
0.02%
iShares Micro-Cap ETF
๋น์จ0.02%
์ฃผ์ ๋ฐฐ๋น๊ธ
๎์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.
๋ ์ง
๋ฐฐ๋น๊ธ
๊ธฐ์ค์ผ
์ง๊ธ์ผ
๋ฐฐ๋น๋ฝ์ผ
๋ฐ์ดํฐ ์์
์ฃผ์ ๋ถํ
๎๋ ์ง
์ ํ
๋น์จ
Jun 01, 2023
Merger
10โ1
Jun 01, 2023
Merger
10โ1
Jun 01, 2023
Merger
10โ1
Jun 01, 2023
Merger
10โ1
๋ ์ง
์ ํ
๋น์จ
Jun 01, 2023
Merger
10โ1
Jun 01, 2023
Merger
10โ1
Jun 01, 2023
Merger
10โ1
Jun 01, 2023
Merger
10โ1
์์ฃผ ๋ฌป๋ ์ง๋ฌธ
Elicio Therapeutics Inc์ ์์ 5๋ ์ฃผ์ฃผ๋ ๋๊ตฌ์ธ๊ฐ์?
๎Elicio Therapeutics Inc์ ์์ 5๋ ์ฃผ์ฃผ๋ ๋ค์๊ณผ ๊ฐ์ต๋๋ค:
GKCC, LLC๋ 5.42M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 33.15%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Knoll Capital Management, LLC๋ 630.91K์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 3.86%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Clal Biotechnology Industries Ltd๋ 481.73K์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 2.95%๋ฅผ ์ฐจ์งํฉ๋๋ค.
The Vanguard Group, Inc.๋ 454.62K์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 2.78%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Actyus Private Equity SGIIC, S.A.๋ 856.38K์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 5.24%๋ฅผ ์ฐจ์งํฉ๋๋ค.
GKCC, LLC๋ 5.42M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 33.15%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Knoll Capital Management, LLC๋ 630.91K์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 3.86%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Clal Biotechnology Industries Ltd๋ 481.73K์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 2.95%๋ฅผ ์ฐจ์งํฉ๋๋ค.
The Vanguard Group, Inc.๋ 454.62K์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 2.78%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Actyus Private Equity SGIIC, S.A.๋ 856.38K์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 5.24%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Elicio Therapeutics Inc์ ์์ 3๋ ์ฃผ์ฃผ ์ ํ์ ๋ฌด์์ธ๊ฐ์?
๎Elicio Therapeutics Inc์ ์ฃผ์ ์ฃผ์ฃผ ์ ํ ์์ 3๊ฐ์ง๋
GKCC, LLC
Knoll Capital Management, LLC
Clal Biotechnology Industries Ltd์ ๋๋ค.
GKCC, LLC
Knoll Capital Management, LLC
Clal Biotechnology Industries Ltd์ ๋๋ค.
Elicio Therapeutics Inc(ELTX)์ ์ฃผ์์ ๋ณด์ ํ ๊ธฐ๊ด์ ๋ช ๊ฐ์ ๋๊น?
๎2025Q4 ๊ธฐ์ค์ผ๋ก, Elicio Therapeutics Inc์ ์ฃผ์์ ๋ณด์ ํ ๊ธฐ๊ด์ ์ด 58๊ณณ์ด๋ฉฐ, ์ด๋ค์ด ๋ณด์ ํ ์ฃผ์์ ์ด ๊ฐ์น๋ ์ฝ 2.05M๋ก ์ ์ฒด ๋ฐํ ์ฃผ์์ 11.00%๋ฅผ ์ฐจ์งํฉ๋๋ค. ์ด๋ 2025Q3 ๋๋น -0.96% ์ฆ๊ฐํ ์์น์
๋๋ค.
Elicio Therapeutics Inc์ ์ต๋ ์์ต์์ ๋ฌด์์ธ๊ฐ์?
๎-- ๊ธฐ์ค, Elicio Therapeutics Inc์ -- ๋ถ๋ฌธ์ด ๊ฐ์ฅ ๋์ ๋งค์ถ์ ๊ธฐ๋กํ์ผ๋ฉฐ, ๊ธ์ก์ --๋ก ์ ์ฒด ๋งค์ถ์ --%๋ฅผ ์ฐจ์งํ์ต๋๋ค.
